CALYXTPAR |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.59 USD | -.--% |
|
+2.93% | -10.44% |
| May. 09 | Cibus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 09 | Transcript : Cibus, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -10.44% | 384M | D+ | ||
| +11.73% | 226B | B | ||
| +9.53% | 188B | B- | ||
| +14.63% | 137B | B- | ||
| +27.47% | 108B | A- | ||
| -0.04% | 63.19B | A- | ||
| +13.73% | 52.26B | B+ | ||
| +4.86% | 51B | B+ | ||
| +7.72% | 43.89B | A | ||
| +7.86% | 38.07B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- CLXT Stock
- Ratings CALYXTPAR
